Inteb

Budesonide, the active ingredient in Inteb, is a corticosteroid presented as an oral formulation for systemic use. It exerts anti‑inflammatory effects by binding glucocorticoid receptors, thereby decreasing cytokine production and immune cell activation. Clinically, it is indicated for the management of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, aiming to induce and maintain remission in adult patients.

GNH USA supplies Inteb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring product quality through stringent manufacturing and regulatory standards.

Budesonide (Inteb) is used in inflammatory bowel disease management to control mucosal inflammation. - Crohn's disease: reduces intestinal inflammation and assists in inducing remission. - Ulcerative colitis: diminishes colonic inflammation and supports remission induction. - Maintenance of Crohn's disease remission: helps sustain disease control after induction. - Maintenance of ulcerative colitis remission: aids in preventing relapse after initial therapy.

Budesonide may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Abdominal pain: discomfort in the stomach area. - Upper respiratory tract infection: mild cold‑like symptoms. - Oral candidiasis: fungal infection of the mouth. - Increased blood glucose: transient rise in glucose levels.

Serious or Rare Side Effects: - Adrenal suppression: reduced endogenous cortisol production. - Severe infection: heightened risk of bacterial or fungal infections. - Osteoporosis: decreased bone mineral density with long‑term use. - Cushing's syndrome: signs of excess glucocorticoid exposure. - Hypersensitivity reactions: rash, angioedema, or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications. - Monitor adrenal function: assess for signs of insufficiency during and after treatment. - Assess infection risk: avoid use in patients with active systemic infections. - Use caution in hepatic impairment: dose adjustments may be required. - Do not discontinue abruptly: taper the dose to prevent withdrawal. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Budesonide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure and risk of adverse effects. - Live vaccines: immunosuppression can reduce vaccine efficacy and increase infection risk.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): budesonide may enhance anticoagulant effect, requiring INR monitoring. - Antidiabetic agents: glucocorticoid effect may raise blood glucose, necessitating dose adjustments. - CYP3A4 inducers (e.g., rifampin): may reduce budesonide concentrations and diminish therapeutic effect.